Mark Esposito *17 MOL
Entrepreneur, Scientist, Mentor
Founder and Chief Science Officer, Kayothera
Mark Esposito is the founder of Kayothera, a preclinical-stage biotechnology company developing first-in-class retinoid nuclear receptor antagonists for multiple diseases, and the principal at Meagi, a consultancy with expertise in preclinical therapeutic development. Esposito received his B.A. from Middlebury College and his Ph.D. in molecular biology from Princeton while working in the laboratory of Yibin Kang. Esposito’s academic work focused on identifying the fundamental mechanisms driving phase separation in cancer, the importance of glycobiology to bone metastasis and the development of new cancer immunotherapies. He founded Kayothera out of his academic work at Princeton and served as the CEO through both seed and series A investments. He is currently the chief science officer at Kayothera and has successfully developed three pipeline candidates from discovery to completion of investigational new drug application-enabling work.